The human skeleton is affected by mutations in low-density lipoprotein receptor-related protein 5 (LRP5). To understand how LRP5 influences bone properties, we generated mice with osteocyte-specific expression of inducible Lrp5 mutations that cause high and low bone mass phenotypes in humans. We found that bone properties in these mice were comparable to bone properties in mice with inherited mutations. We also induced an Lrp5 mutation in cells that form the appendicular skeleton but not in cells that form the axial skeleton; we observed that bone properties were altered in the limb but not in the spine. These data indicate that Lrp5 signaling functions locally, and they suggest that increasing LRP5 signaling in mature bone cells may be a strategy for treating human disorders associated with low bone mass, such as osteoporosis.
The skeleton is influenced by environmental, genetic, neurologic, endocrine, paracrine and autocrine factors. Efforts to identify pathways that affect bone health have been facilitated by genetic studies in individuals with abnormally low or abnormally high bone mass [1] [2] [3] [4] [5] [6] . A key role for LRP5 was identified using these approaches. Individuals with osteoporosis-pseudoglioma syndrome, a disorder involving low bone mass, have loss-of-function mutations in LRP5 (refs. 1,7), whereas heterozygous missense mutations in LRP5 have been observed in individuals with dominantly inherited high bone mass (HBM) 2, 3, 8 .
The mechanism by which LRP5 regulates bone mass has not been fully delineated. Studies in several laboratories indicate that LRP5 can function as a co-receptor in the canonical Wnt signaling cascade in vivo and ex vivo 1, 3, [9] [10] [11] [12] . Furthermore, mice with genetic alterations in other components of the canonical Wnt signaling pathway have been shown to have alterations in bone mass; this is consistent with this pathway's importance in bone mass accrual 10, [13] [14] [15] [16] . A direct role for LRP5 in osteoblast-lineage cells has been proposed based on studies in mice that overexpress LRP5 cDNAs driven by a rat type-1 collagen promoter 17 . However, phenotypes resulting from transgenedriven overexpression of a protein may not accurately reflect the endogenous protein's function.
We generated two lines of Lrp5 knock-in mice (see Supplementary  Methods) , each containing a missense mutation found in human HBM. Both missense mutant proteins had been shown to be comparable to wild-type human LRP5 in their ability to transduce canonical Wnt signaling in transfected cells 9 . However, the mutants differed in their efficiency of trafficking to the cell surface, as well as in their interactions with the chaperone protein MESD and the extracellular inhibitors Dickkopf homolog 1 (DKK1) and sclerostin (SOST) 9, 11, 18 . We designed the Lrp5 knock-in alleles to function as HBM-causing alleles after Cre recombinase (Cre)-mediated recombination. This enabled us to compare the effect of inheriting an Lrp5 HBM allele, such that the allele is present in all cells, with the effect of activating an Lrp5 HBM allele in a cell type-specific or tissue-specific manner. We also generated mice with floxed wild-type (WT) Lrp5 alleles that could be converted to knockout alleles after Cre-mediated recombination. This enabled us to compare the effect of inheriting inactive Lrp5 with the effect of inactivating Lrp5 in a cell type-specific or tissue-specific manner.
RESULTS
Inherited Lrp5 HBM alleles increase bone mass Exon 3 of mouse Lrp5 encodes the residues we mutated to HBMcausing alleles (p.G171V and p.A214V). Our targeting vector incorporated a neomycin-resistance cassette (Neo R ) flanked by loxP sites (Fig. 1a) . Because Neo R is driven by a strong promoter and transcribed in the opposite direction of Lrp5, we anticipated that Neo R would interfere with Lrp5 transcription and thereby cause Lrp5 Neo Rcontaining HBM alleles (G N and A N ) to be poorly expressed. Mice with the Lrp5 genotypes G N /G N or A N /A N had reduced expression compared to WT mice (Fig. 1b) . Cre-mediated excision of Neo R (G and A) enhanced expression such that mice with genotypes G/G or A/A had expression that was comparable to WT expression ( Fig. 1b) . We designed a PCR assay to distinguish Lrp5 WT, Neo R -containing (G N or A N ), and Neo R -excised HBM (G or A) alleles ( Fig. 1c) .
After creating conditional alleles that can be converted to HBMcausing alleles by Cre, we investigated whether mice with inherited Lrp5 HBM alleles (Neo R -excised) recapitulated the human HBM phenotype. Compared with WT mice, mice with Lrp5 HBM alleles had increased bone mass ( Fig. 1d,e, Supplementary Fig. 1 and Supplementary Table 1 ), bone strength ( Fig. 1f ) and bone formation rates ( Fig. 1g) . When we intercrossed mice with Lrp5 HBM alleles to BAT-lacZ transgenic mice (BAT-lacZ is a Wnt reporter mouse strain that expresses lacZ in response to canonical Wnt signaling 19 ), we observed increased lacZ expression in cortical bone homogenates from the offspring that inherited Lrp5 HBM alleles compared to offspring that inherited WT alleles; we also observed increased expression of Axin2 (encoding axin-2), a known Wnt target gene 20 , in mice with Lrp5 HBM alleles compared to mice with WT alleles (Supplementary Fig. 1 ).
Lrp5 HBM expression in osteocytes increases bone mass
Mice heterozygous for alleles G N or A N (see Supplementary Methods) had bone mass comparable to WT mice ( Fig. 2a, Supplementary Supplementary Table 2 ), thereby indicating that decreased expression of the G N or A N allele was partially compensated for by its increased function. Because Cre converts alleles G N and A N to alleles G and A, respectively, we tested whether increasing Lrp5 HBM allele expression in osteocytes would affect bone mass. We crossed mice with G/G N or A/A N genotypes to mice hemizygous for a transgene, Dmp1-Cre, in which a dentin matrix protein 1 (encoded by Dmp1) regulatory sequence drives Cre expression in osteocytes 21 .
Figs. 2 and 3 and
Offspring that inherited the Lrp5 HBM allele (G or A) had high bone mass, independent of whether they inherited Dmp1-Cre (Fig. 2b,c) . Offspring that inherited the Lrp5 Neo R -containing allele (G N or A N ), and not Dmp1-Cre, had normal bone mass (Fig. 2b,c and Supplementary Figs. 3 and 4) . Offspring that inherited the Lrp5 Neo R -containing allele (G N or A N ) and Dmp1-Cre had increased bone mass (Fig. 2b,c and Supplementary Figs. 3 and 4) , thus supporting a local role for Lrp5 signaling in bone. We confirmed that the Dmp1-Cre transgene was expressed in bone ( Fig. 2d) . Furthermore, conversion of alleles G N and A N to alleles G and A, respectively, in mouse osteocytes, had the same effect on bone as did inheriting G and A alleles ( Fig. 2e,f and Supplementary Fig. 4 ).
We also found that Dmp1-Cre was expressed in tissues other than bone ( Supplementary Fig. 5 ). This observation led us to test whether Lrp5 signaling outside of bone tissue was responsible for increased bone mass. We began by evaluating the role of Lrp5 in the intestine, as a model has been proposed in which Lrp5 affects bone mass by regulating serotonin (5HT) production in the duodenum 22 . In this model, Lrp5 has no direct role in bone; rather, it affects bone mass accrual by regulating the expression of the enzyme tryptophan hydroxylase 1 (Tph1) in the duodenum 22 . Tph1 is the rate-limiting enzyme for peripheral 5HT synthesis, and the intestine is the principal source of 5HT found in blood 23, 24 ; another tryptophan hydroxylase (Tph2) produces 5HT in the central nervous system [24] [25] [26] . We crossed mice with G/G N or A/A N genotypes to mice hemizygous for a transgene, Vil1-Cre, that uses a villin 1 (encoded by Vil1) regulatory sequence to drive Cre expression in intestinal stem cells 27 , from which 5HT-producing enterochromaffin cells are derived. We found that conversion of alleles G N or A N to alleles G or A, respectively, in the intestine had no effect on bone mass (Fig. 2b,c and Supplementary  Fig. 3 ). In addition, we found that Vil1-Cre drove Cre expression in the intestine but not in bone ( Fig. 2d and Supplementary Fig. 5 ).
Although our Vil1-Cre experiments excluded a substantial role for intestinal Lrp5 expression in the endocrine regulation of bone mass, they did not exclude the possibility that Lrp5 could function elsewhere to regulate bone mass indirectly. Therefore, we tested whether Lrp5 acted locally or systemically to affect bone mass by crossing mice with A/A N genotypes to mice hemizygous for a transgene, Prrx1-Cre; this transgene uses a paired-related homeobox 1 (encoded by Prrx1) regulatory sequence to drive Cre expression in cells that form bone in the appendicular skeleton but not in the axial skeleton 28 (Supplementary  Fig. 6 ). Conversion of A N to A in cells that form the appendicular but not the axial skeleton increased bone mass in the limb but not in the spine ( Fig. 2g and Supplementary Fig. 6 ). nAture medicine VOLUME 17 | NUMBER 6 | JUNE 2011 6 8 7
Loss of Lrp5 in osteocytes decreases bone mass
We created a conditional knockout allele of Lrp5 by flanking exon 2 with loxP sites (Fig. 3a) . Deletion of this exon by Cre-mediated recombination resulted in the production of an Lrp5 transcript that was frameshifted and that had a premature termination codon shortly after the signal peptide (data not shown). We developed a PCR assay for Lrp5 WT, floxed and Cre-excised alleles (Fig. 3b) .
We found that bone mass in homozygous floxed (Lrp5 f/f ) mice was indistinguishable from WT mice ( Fig. 3) . Furthermore, bone mass in mice homozygous for Cre-excised alleles was low, similar to other lines of Lrp5-knockout mice 10,29 (data not shown). We inactivated Lrp5 in osteocytes by crossing Lrp5 f/f mice to Lrp5 f/f mice that were also hemizygous for Dmp1-Cre. We confirmed that Dmp1-Cre expression inactivated Lrp5 in bone and not in 
After Flp excision
After Cre excision duodenum (Fig. 3c) . Compared to their littermates, mice lacking Lrp5 activity in osteocytes had reduced bone mass ( Fig. 3d and Supplementary Fig. 5 ). We tested whether inactivation of Lrp5 in the intestine would decrease bone mass by crossing Lrp5 f/f mice to Lrp5 f/f mice that were also hemizygous for Vil1-Cre; we observed no significant effect on bone mass ( Fig. 3e and Supplementary Fig. 5d ).
Lrp5 genotype does not affect intestinal 5HT synthesis
Our data support a mechanism in mice in which Lrp5 functions via the canonical Wnt pathway in osteocytes to regulate bone mass rather than regulating bone mass indirectly via other tissues. However, independent of its role in bone, Lrp5 could also regulate 5HT production in the gut. We measured blood 5HT in mice with different Lrp5 genotypes, but we saw no association between genotype and the amount of 5HT ( Fig. 4a and Supplementary Fig. 7) . We also measured 5HT content in different regions of the intestine in Lrp5 WT and knockout mice and found only a small decrease in knockout mice (Fig. 4b) ; this is contrary to what would be predicted if the lack of Lrp5 increased Tph1 expression 22 . We also did not observe a correlation between whole blood 5HT content and bone mass in individual mice (Fig. 4c) . Finally, with real-time PCR we quantified the level of Tph1 transcript in RNA extracted from the duodenums of mice with different Lrp5 genotypes but detected no differences among them (Fig. 4d) .
Peripheral 5HT synthesis does not affect bone mass
The model 22 by which LRP5 controls serotonin synthesis and regulates bone mass via an endocrine rather than a Wnt-based local mechanism was unexpected 30 . It suggested that bone health could be improved by pharmacologically inhibiting either intestinal serotonin synthesis or the hormone's action on osteoblasts 31 . In fact, pharmacologic inhibition of Tph1 in the intestine was reported to increase bone mass in ovariectomized mice and rats to the same degree as a US Food and Drug Administration-approved anabolic bone therapy, intermittent parathyroid hormone (teriparatide) treatment 32 . Because 5HT in whole blood is nearly absent in Tph1 −/− mice 23, 24 , we measured bone mass in Tph1 −/− and WT mice. After correcting for multiple testing, there were no significant differences in bone mass between Tph1 −/− and WT mice ( Fig. 5 and Supplementary Table 3) . It is possible that Tph1 −/− mice activate compensatory pathways that keep bone mass at WT levels. This could explain why an increase in bone mass was reported when Tph1 was conditionally inactivated only in the intestine 22 , or when a small molecule was used to inhibit Tph1 in the intestine 32 . Therefore, we treated sham-operated and ovariectomized mice and rats for 6 weeks with a small-molecule Tph1 inhibitor, LP-923941, which is the active enantiomer of a compound, LP-533401 (Supplementary Table 4) , that has been previously reported to increase bone mass 32 . We selected the LP-923941 dose of 250 mg per kg per day used in our pharmacology studies from a preliminary 7-d dose-response study in mice (Fig. 6a) .
We found that treating sham-operated and ovariectomized mice with LP-923941 for 6 weeks reduced 5HT content in whole blood by 42% at 2 weeks (2715 versus 4813 ng ml −1 , P < 0.001) and 44% at 6 weeks (2543 versus 4359 ng ml −1 , P < 0.001) without influencing brain 5HT content (0.49 versus 0.50 µg g −1 ) or turnover, as indicated by 5-hydroxyindoleacetic acid levels (0.231 versus 0.229 µg g −1 ). The ability of LP-923941 to reduce 5HT synthesis in all segments of the intestine was not influenced by ovariectomy (P < 0.001, Fig. 6b ) and was similar in the 7-d dose-response and 6-week pharmacology studies. Reductions in whole blood content and intestinal serotonin content did not influence the amount of serum procollagen 1 N-terminal peptide (P1NP) (a marker of bone formation), trabecular bone mass or cortical bone mass in either sham-operated or ovariectomized mice ( Fig. 6c and Supplementary Fig. 8) . In contrast, we found that teriparatide increased bone formation and bone mass in sham-operated and ovariectomized mice ( Fig. 6c and Supplementary Fig. 8) .
We also treated sham-operated and ovariectomized rats for 6 weeks with LP-923941, which resulted in a reduction of intestinal 5HT content by 51% and 46%, respectively, compared to vehicle-treated controls (Fig. 6d) . The reduction in intestinal 5HT content was not accompanied by any change in trabecular or cortical bone mass of the femur, nor did it result in any changes in trabecular bone mass (c) Graphs depicting lumbar spine aBMD, as measured by DEXA, in the same mice described in panel a. The numbers of mice studied are indicated. Error bars show means ± s.d. *P < 0.05 versus WT mice using an unpaired t test; none of these differences remain significant after correcting for multiple testing.
of the fifth lumbar vertebra (Fig. 6d) . However, daily injections with teriparatide significantly increased bone mass in both the femur and the vertebral body of sham-operated and ovariectomized rats ( Fig. 6d  and Supplementary Fig. 9 ).
DISCUSSION
Our in vivo data indicate that Lrp5 acts in osteocytes and perhaps in some late-stage osteoblasts to effect changes in bone mass via canonical Wnt signaling. Axin2, a downstream target of Wnt signaling, is more highly expressed in bone from mice with HBM-causing alleles, as is a lacZ reporter of canonical Wnt signaling (Supplementary Fig. 1) .
These results are consistent with in vitro studies of LRP5-mediated Wnt signaling, which reported that HBM mutations cause LRP5 to be less inhibited by the endogenous inhibitors DKK1 and SOST than WT LRP5 9, 11, 33, 34 . DKK1 is expressed by many cells, including osteocytes, and a complete lack of Dkk1 is embryonic lethal; however, mice with partial loss-of-function mutations in Dkk1 have increased bone mass, which is consistent with this protein acting as a negative regulator of bone formation 16, 35 . SOST is principally expressed by mature osteocytes, and when it is genetically absent in humans and in mice it causes a phenotype that is similar to the phenotype resulting from HBM-causing mutations in LRP5 4, 5, 15 . The strong expression of SOST by mature bone cells suggests that it functions as a tonic negative regulator of new bone formation (Supplementary Fig. 10) . In mice, the mechanical loading of bone, which is a potent inducer of new bone formation in vivo, reduces Sost expression by osteocytes 36 and increases the expression of Wnt target genes 37, 38 . Therefore, by being less sensitive to endogenous inhibitors, Lrp5 HBM mutants are likely to induce new bone formation in the absence of mechanical load or at lower mechanical load (Supplementary Fig. 10) . Conversely, mice that lack Lrp5 have a blunted anabolic response to mechanical load 39 , which is consistent with insufficient Wnt signaling in Lrp5 −/− osteocytes (Supplementary Fig. 10 ).
Lrp5 is also expressed during osteoblast commitment and differentiation 1, 40 . Therefore, similarly to other signaling pathways that influence cellular differentiation at several stages 41, 42 , Lrp5 signaling may influence other aspects of osteoblast differentiation. This speculation is compatible with studies noting that, in the absence of canonical Wnt signaling, differentiating mesenchymal stem cells adopt chondrogenic and adipogenic fates instead of osteoblastic fates [43] [44] [45] [46] . However, these studies blocked canonical Wnt signaling by conditionally inactivating β-catenin. LRP5 and its closest-related mammalian paralog, LRP6, are both able to transduce Wnt signaling in vitro, and they have overlapping and nonredundant roles in vivo during gastrulation and skeletal patterning 10, 47 . Therefore, LRP6 may be able to compensate for LRP5 during some stages of osteoblast differentiation.
We found that inducing the Lrp5 HBM allele in osteocytes had the same effect on bone mass as was observed when the active Lrp5 HBM allele was inherited. Conversely, Dmp1-Cre-mediated inactivation of Lrp5 in osteocytes caused a decrease in bone mass compared to WT mice. Taken together, these data indicate that Lrp5 signaling by mature bone cells regulates bone mass and, in the case of the HBMcausing mutation, is sufficient to recapitulate the inherited HBM phenotype. Further support for this conclusion derives from studies in which we caused the Lrp5 HBM allele to become active in cells that contribute to the appendicular skeleton but not to the axial skeleton. Bone mass increased only at skeletal sites where the HBM-associated allele was active.
Our results do not support a model in which Lrp5 regulates bone mass via the regulation of peripheral 5HT synthesis in the duodenum 22 . When we activated Lrp5 HBM or inactivated WT Lrp5 in 5HT-producing enterochromaffin cells, we found no effect on bone mass. In addition, we found no Lrp5 genotype-specific differences in the amount of whole blood 5HT, nor did we observe any effect on bone mass after genetically or pharmacologically lowering peripheral 5HT production. Currently, we do not know the origin of the difference in the results of our study and those of prior studies 22, 32 . Perhaps differences in the design of the Lrp5 conditional alleles, the transgenic mice that were used to produce cell type-specific Cre recombination within bone and intestine, the assays used to measure 5HT, the use of conditional versus global Tph1 knockout alleles, the vivariums in which the mice were raised or the trial design for pharmacologic inhibition of Tph1 in ovariectomized mice and rats account for the differing results (also see Supplementary Methods) .
We created mice with knock-in HBM-causing alleles in which the gene's intron-exon structure remained intact. An earlier study inserted an HBM-causing Lrp5 cDNA with a C-terminal Flag tag into the first exon of Lrp5 22 . We used a Dmp1-Cre transgene that is expressed in osteocytes and in some late-stage osteoblasts, whereas the other study 22 used a Col1a1-Cre transgene (with a 2.3-kb collagen, type 1, α-1 promoter to drive Cre expression) that is expressed earlier in the process of osteoblastic differentiation 48 . We used a different Vil1-Cre transgenic mouse line than the earlier study 22 , although both lines expressed Cre in intestinal stem cells. Nevertheless, it remains possible that inefficient Cre-mediated recombination or off-target sites of Cre expression account for some of the divergent results between our study and the other study 22 .
We found no association between Lrp5 genotype and serum 5HT concentration. However, the concentration of 5HT in serum depends on the efficiency of 5HT release from platelets during clot formation, which, in turn, is affected by the collection and clotting method as well as the clotting time 49 . As such, serum measures can be unreliable within and across studies. In contrast, as long as the capacity of platelets to store 5HT is not exceeded, whole blood 5HT content correlates well with free circulating 5HT concentration 50 . Therefore, we also measured whole blood 5HT by HPLC 23 . The amount of 5HT in whole blood did not correlate with Lrp5 genotype or with bone mass. Because the amount of whole blood 5HT can be influenced by other factors, such as inflammation and infection, it is possible that environmental differences between the present study and the earlier study 22 account for the divergent 5HT results.
We studied bone mass in Tph1 −/− mice, whereas Tph1 was inactivated using Vil1-Cre in the previous study 22 . Tph1 −/− mice may have activated compensatory pathways to normalize bone mass, whereas mice with conditional Tph1 inactivation may not. We tested this possibility by pharmacologically inhibiting 5HT synthesis in the intestine. We used the active enantiomer of a small-molecule inhibitor previously reported to affect bone mass 32 . We studied mice that had undergone ovariectomy a year before receiving the pharmacologic agent and found no effect on bone mass compared to vehicle-treated controls (Fig. 6) ; in contrast, teriparatide had a strong anabolic effect. We examined aged ovariectomized mice, because women in their first decade after menopause are a major target population for anabolic osteoporosis therapy. However, our ovariectomy model differed from that used in the earlier study in which mice had undergone ovariectomy less than 2 months before receiving the pharmacologic agent 32 . Therefore, we used a rat model in which we began pharmacologic Tph1 inhibition 5 weeks after ovariectomy; this is within the time frame used in the previous study 32 . Again, we observed no effect of Tph1 inhibition on bone mass compared to vehicle-treated controls, whereas teriparatide had a robust bone anabolic effect (Fig. 6) . However, because we only studied the active enantiomer, we cannot exclude the possibility that the inactive enantiomer increases bone mass via a mechanism that is independent of Tph1 inhibition.
Although Lrp5 genotype may affect peripheral serotonin synthesis in some contexts 22 , in the present study we did not observe Lrp5mediated effects on peripheral 5HT abundance or Tph1-mediated effects on bone mass. Therefore we think it unlikely that the mechanism by which LRP5 normally affects human bone mass involves intestinal 5HT synthesis. Instead, our data suggest that LRP5 functions in bone to control bone mass, and they are consistent with the notion that the receptor participates in the adaptive response of bone to mechanical load (Wolff 's law) 51 . Therapies aimed at enhancing these functions of LRP5 in humans may benefit individuals who have skeletal fragility as a result of low bone mass.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website.
